(21 Feb 2021) Dexamethasone- 60 mg and 150 mg was associated with reduced mortality

Dexamethasone use and Mortality in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study

https://doi.org/10.1111/bcp.14784

Of 12,217 adult patients hospitalized with a positive COVID-19 PT-PCR test, 171 (1.4%) received dexamethasone orally or by intravenous perfusion during the visit. Among patients who required respiratory support, the end-point occurred in 10/63 (15.9%) patients who received dexamethasone and 298/1,129 (26.4%) patients who did not. In this group, there was a significant association between dexamethasone use and reduced mortality in the primary analysis (HR, 0.46; 95%CI, 0.22 to 0.96, p=0.039). Among patients who did not require respiratory support, there was no significant association between dexamethasone use and the endpoint. In this multicenter observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support.